Media Library

A cancer patient's frozen T-Cells arrive at a Novartis facility to be reengineered.

SMS for Life training session teaching healthcare workers how to use text messaging to monitor stock levels of life-saving antimalarials. In Kenya, Machacos district, SMS for Life also includes patient surveillance data on the testing of malaria patients and the use of artemisinin-based combination therapies (ACTs).

SMS for Life is an innovative public-private partnership led by Novartis under the umbrella of the Roll Back Malaria Partnership. The program has been rolled out across Tanzania and pilots are taking place in Ghana and Kenya.

The Frozen T-Cells of a cancer patient.

Mode of Action of a CGRP Receptor Blocker, calcitonin gene-related peptide (CGRP), CGRP receptor complex, CGRP receptor blocker targeting the receptor complex.

Malaria researchers in Nairobi, Kenya, are working to stay one step ahead of the malaria parasite in order to provide innovative treatments to support elimination efforts.

Rural village, Lake Victoria region, Kenya: A teacher talks to school children about prevention and proper treatment of malaria. Simple tools like bed nets, effective medicines and indoor spraying have helped some African countries to reduce malaria deaths by 50% or more.

Rapid Diagnostic Tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites in human blood. They allow the testing of people who cannot access diagnosis based on microscopy.

In China, Novartis works with about 100,000 farmers who cultivate Artemisia annua, a crucial plant in the production of our antimalarial treatment.

We source our antimalarial treatment’s active pharmaceutical ingredients from China. Once the farming is done, the technical process begins. After the artemisinin has been extracted from the leaves, it is again dissolved in ethanol and processed for higher purity and quality. Here, a facility for the processing of artemisinin.

Deliveries of this child-friendly antimalarial hit the 300 million mark. This child-friendly ACT is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT).

Antimalarial raw material before it is made into pills.